Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: Insights into mechanism

Clinical Nephrology

Volumn 60, Issue 1, 2003, Pages 13-21

  Panos, J ^a   Michelis, M F ^a   DeVita, M V ^a   Lavie, R H ^a   Wilkes, B M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin type 1 receptor blockers; Angiotensin converting enzyme inhibitors; Combination therapy; Losartan; Urinary protein excretion

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; LOSARTAN; QUINAPRIL; RAMIPRIL;

ADRENAL GLAND; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; GLOMERULUS; HORMONE ACTION; HORMONE INHIBITION; HUMAN; KIDNEY DISEASE; KIDNEY PARENCHYMA; MALE; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; PROTEIN URINE LEVEL; PROTEINURIA; RECEPTOR BLOCKING; URINARY EXCRETION;

EID: 0038044777     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp60013     Document Type: Article

References (42)

1. Agarwal R 2001 Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59: 2282-2289
2. Anderson S, Meyer TW, Rennke HG, Brenner BM 1985 Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619
3. Anderson S, Tarnow L, Rossing P, Hansen BV, Parving HH 2000 Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57: 601-606
4. Arteaga J, Petrina E, Anda E, Calderon D, Sorbet M, Asirón M 2000 The antiproteinuric effect of enalapril is potentiated by losartan in normotensive patients with diabetic nephropathy (Abstract). Am J Hypertens 13 (Part 2): 117A
5. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J 1997 Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29: 634-640
6. Bellucci A, Wilkes BM 1984 Mechanism of sodium modulation of glomerular angiotensin receptors in the rat. J Clin Invest 74: 1593-1600
7. Bohrer MP, Deen WM, Robertson CR, Brenner BM 1977 Mechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol 233: F13-21
8. Brenner BM, Cooper ME, Zeeuw DD, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
9. Cattran DC, Greenwood C, Ritchie S 1994 Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23: 247-254
10. Chrysostomou A, Becker G 2001 Spironolactone in addition to ace inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: 925-926
11. Donadelli R, Abbate M, Zanchi C, Corna D, Tomasoni S, Benigni A, Remuzzi G, Zoja C 2000 Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation. Am J Kidney Dis 36: 1226-1241
12. Ferrari P, Marti H, Pfister M, Frey FJ 2002 Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 20: 125-130
13. Hebert LA, Falkenhain ME, Nahman NS, Cosio FG, O'Dorsio TM 1999 Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 19: 1-6
14. Heeg JE, de Jong PE, Van Der Hem GK, de Zeeuw D 1987 Reduction of proteinuria by angiotensin-converting enzyme inhibition. Kidney Int 32: 78-83
15. Hollenberg NK, Fisher NDL, Price DA 1998 Pathways for angiotensin II generation in intact human tissue - evidence from comparative pharmacological interruption of the renin system. Hypertension 32: 387-392
16. Hostetter TH 2001 Prevention of end-stage renal disease due to type 2 diabetes (editorial). N Engl J Med 345: 910-912
17. Hsu C, Bates DW, Kuperman GJ, Curhan GC 2001 Blood pressure and angiotensin-converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. Am J Hypertens 14: 1219-1225
18. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ 1993 Multiple autocrine growth factors modulate vascular smooth muscle growth response to angiotensin II. J Clin Invest 91: 2268-2274
19. Jerums G, Allen T, Campbell D, Cooper M, Gilbert R, Hammond J, Raffaele J, Tsalamandris C 2001 Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 37: 890-899
20. Klahr S, Morrisey J 1997 Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int 52 (Suppl 63): S111-114
21. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB 2002 Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 39: 159-164
22. Lacourciére Y, Bélanger A, Godin C, Hallé J, Ross S, Wright N, Marion J 2000 Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 58: 762-769
23. Lewis EJ, Lawrence G, Hunsicker MD, Bain RP, Rohde RD 1993 The effects of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462
24. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I 2001 Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860
25. Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, Ponticelli C, Ritz E, Zucchelli P 1996 Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renaf insufficiency. N Engl J Med 334: 939-945
26. Mento PF, Wilkes BM 1987 Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 9 (Suppl III): S42-48
27. Mento PF, Holt WF, Murphy WR, Wilkes BM 1989 Combined renin and converting enzyme inhibition in rats. Hypertension 13: 741-748
28. Meyer TW, Anderson S, Rennke HG, Brenner BM 1985 Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency. Am J Med 79 (Suppl 3C): 31-36
29. Meyer TW, Anderson S, Rennke HG, Brenner BM 1987 Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31: 752-759
30. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME 2000 Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin-dependent diabetes: the candesartan and lisinopril mircroalbuminuria (CALM) study. BMJ 321: 1440-1444
31. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR 1990 Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 15: 276-282
32. Nussberger J, Brunner DB, Waeber B, Brunner HR 1986 Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 8: 476-482
33. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Anderson S, Arner P 2001 The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878
34. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker L, King AJ, Klahr S, Massry SG, Seifter J 1995 Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 123: 754-762
35. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M 1993 Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581
36. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G 1990 Angiotensin-converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 85: 541-549
37. Rocha R, Chander PN, Zuckerman A, Steir C 1999 Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237
38. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF 2000 Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens 18: 89-95
39. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R 1999 Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33: 851-856
40. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM 2001 Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38: 18-25
41. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A 1993 Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 91: 1269-1281
42. Wilkes BM, Pion I, Sollott S, Michaels S, Kiesel G 1988 Intrarenal renin-angiotensin system modulates glomerular angiotensin receptors in the rat. Am J Physiol 254: F345-350